CollPlant Holdings (CLGN) plans to raise $22 million in an IPO on Thursday, December 8th. The company plans to issue 3,500,000 shares at $6.23 per share.

CollPlant Holdings has a market-cap of $35.2 million.

Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

CollPlant Holdings provided the following description of their company for its IPO: “(Note:¬†Our ordinary shares currently trade on the Tel Aviv Stock Exchange, or TASE, under the symbol “CLPT,” and the ADSs are currently quoted on the OTCQX marketplace, or OTCQX, under the symbol “CQPTY.”) We are a clinical-stage regenerative medicine company focused on developing and commercializing tissue repair products, initially for the orthobiologics and advanced wound care markets. Our product candidates are based on our rhCollagen, a form of human collagen produced with our proprietary plant-based genetic engineering technology. We believe our technology is the only commercially viable technology available for the production of genetically engineered, or recombinant, human collagen. “.

CollPlant Holdings was founded in 1981 and has 37 employees. The company is located at 3 Sapir Street, Weizmann Science Park, Ness-Ziona 74140, Israel and can be reached via phone at +972 73 232 5600 or on the web at https://www.collplant.com.

Receive News & Stock Ratings for CollPlant Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Holdings and related stocks with our FREE daily email newsletter.